When a diabetic foot ulcer fails to close despite good wound care and offloading, the bone underneath is often the reason. Diabetic foot osteomyelitis (DFO) is present in a substantial minority of infected foot ulcers — in the most severe soft tissue infections, bone involvement may reach 60% (Senneville et al., Diabetes/Metabolism Research and Reviews, 2020). Because bone infection changes both the antibiotic plan and the surgical plan, and because it carries a materially higher risk of amputation, getting the diagnosis right matters. Yet DFO remains one of the harder diagnoses in wound care: no single test settles the question, and the tests that clinicians rely on agree with each other less often than most people assume.
Why Diagnosis Is Difficult
The practical problem is that the classic reference standard — bone biopsy with histopathology and culture — is not always feasible, and the substitutes are imperfect. A retrospective analysis of 50 consecutive hospitalized patients compared five commonly used tests: the probe-to-bone test, plain radiographs, MRI, and intraoperative bone samples sent for both histology and microbiology. Agreement between tests ranged from only 42% to 62%, and chance-corrected agreement (kappa) ranged from 0.0 to 0.22 — the “poor” to “slight” range. The best-agreeing pair was plain radiography and MRI, at 62% (Meyr et al., Journal of Foot and Ankle Surgery, 2018). The authors’ conclusion was sobering: the individual tests carry high intrinsic unreliability, and the optimal combination is still undefined.
This is why current guidance frames DFO diagnosis as a layered process rather than a single confirmatory test.
The First-Line Layer
Suspicion begins clinically. A positive probe-to-bone test — in which a sterile blunt probe reaches hard, gritty bone at the ulcer base — is the most useful bedside finding, particularly in patients with a high pre-test probability of infection. Inflammatory markers help support, though not establish, the diagnosis; an elevated erythrocyte sedimentation rate is the most consistently informative of these. Plain radiography remains the recommended first imaging study. The 2023 systematic review underpinning the international guidelines concluded that the combination of a positive probe-to-bone test and an elevated ESR supports a diagnosis of DFO, and that plain X-ray should be the first-line imaging examination (Senneville et al., Diabetes/Metabolism Research and Reviews, 2023).
The Advanced Imaging Layer
When doubt persists after clinical assessment and radiography — or when the anatomical extent of infection needs to be mapped before surgery — MRI is the preferred advanced modality, with nuclear medicine techniques reserved for patients in whom MRI is not feasible. Advanced imaging serves a second purpose beyond diagnosis: it can localize the infected bone and thereby improve the yield of a percutaneous biopsy (Woo, Cho, and Park, Journal of Yeungnam Medical Science, 2023).
The Microbiological Layer
Where medical (non-resective) management is being considered, knowing the causative organism substantially improves the odds that the chosen antibiotic is the right one. Guidance is consistent on technique: bone should be sampled either intraoperatively or by percutaneous biopsy that does not pass through the ulcer, in order to avoid contamination by colonizing surface flora. Superficial swab cultures are markedly less accurate than tissue or bone cultures. Bedside percutaneous biopsy has been shown to be both effective and safe when surgical or radiological approaches are unavailable. Next-generation sequencing and other molecular methods reliably identify more organisms than culture, but no study has yet demonstrated that this changes patient outcomes (IWGDF/IDSA, Diabetes/Metabolism Research and Reviews and Clinical Infectious Diseases, 2023).
How Long Should Antibiotics Continue?
Historically, six weeks of systemic antibiotic therapy was standard for DFO. That convention is now under active challenge. In a prospective randomized non-inferiority pilot trial of 93 patients who had undergone surgical debridement, remission occurred in 84% of those treated for three weeks versus 73% of those treated for six weeks, with a similar rate of adverse events in both arms — results statistically non-inferior for the shorter course (Gariani et al., Clinical Infectious Diseases, 2021).
The picture is similar after partial amputation. A post hoc analysis of 171 patients pooled from two randomized trials compared those with residual osteomyelitis at the resection margin to those with clear margins. Patients with clear margins received shorter antibiotic courses, but at 12 months there was no difference in re-ulceration at the same site, re-infection, further amputation, hospitalization, or time to healing. Successful treatment was achieved in roughly 87% of each group (Lavery et al., International Wound Journal, 2024). A separate retrospective cohort of 92 patients with culture-positive proximal bone margins likewise found no significant difference in re-operation or re-admission between courses under four weeks and courses of four weeks or longer (Motaganahalli et al., Journal of Antimicrobial Chemotherapy, 2023).
Clinical Summary
Diabetic foot osteomyelitis should be suspected in any deep, long-standing, or clinically infected foot ulcer, and particularly where a probe-to-bone test is positive and inflammatory markers are elevated. No single test is a true gold standard; diagnosis rests on combining clinical findings, radiography, selective advanced imaging, and — where management hinges on the organism — an uncontaminated bone sample. On the treatment side, the accumulated evidence increasingly supports shorter antibiotic courses after adequate surgical debridement, with three to four weeks appearing non-inferior to six weeks in the trials conducted to date. Larger confirmatory trials are ongoing, and the balance between surgical resection and antibiotic duration remains an area of active investigation.
References
- Senneville É, Lipsky BA, van Asten SAV, Peters EJ. Diagnosing diabetic foot osteomyelitis. Diabetes/Metabolism Research and Reviews. 2020;36(Suppl 1):e3250. doi:10.1002/dmrr.3250
- Senneville É, Albalawi Z, van Asten SA, et al. Diagnosis of infection in the foot of patients with diabetes: A systematic review. Diabetes/Metabolism Research and Reviews. 2024;40(3):e3723. doi:10.1002/dmrr.3723
- Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad527
- Meyr AJ, Seo K, Khurana JS, Choksi R, Chakraborty B. Level of Agreement With a Multi-Test Approach to the Diagnosis of Diabetic Foot Osteomyelitis. Journal of Foot and Ankle Surgery. 2018;57(6):1137–1139. doi:10.1053/j.jfas.2018.05.010
- Woo I, Cho SJ, Park CH. State-of-the-art update for diagnosing diabetic foot osteomyelitis: a narrative review. Journal of Yeungnam Medical Science. 2023;40(4):321–327. doi:10.12701/jyms.2023.00976
- Gariani K, Pham TT, Kressmann B, et al. Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial. Clinical Infectious Diseases. 2021;73(7):e1539–e1545. doi:10.1093/cid/ciaa1758
- Lavery LA, Tarricone AN, Reyes MC, et al. Does complete resection of infected bone improve clinical outcomes in patients with diabetic foot osteomyelitis? International Wound Journal. 2024;21(10):e70072. doi:10.1111/iwj.70072
- Motaganahalli S, Batrouney A, Perera D, Vogrin S, Trubiano JA. Retrospective study of outcomes of short versus long duration of antibiotic therapy for residual osteomyelitis in surgically resected diabetic foot infection. Journal of Antimicrobial Chemotherapy. 2023;78(1):284–288. doi:10.1093/jac/dkac390
Source literature identified via PubMed.
Comments
